Agenus tries again with the FDA
A July meeting with the FDA could determine whether Agenus’s bot-bal combo has a shot at a 2024 filing.
Servier completes its retreat from cell therapy
The sale of remaining rights to Allogene ends acrimony between the two companies.
The month ahead: May’s remaining events
ASCO is fast approaching, but in the meantime Olema will have an important readout.
FDA green and red lights: April 2024
A tumour-agnostic label for Enhertu leads April’s US oncology approvals.
